Introduction
Asthma is a heterogeneous disease that is usually characterized by chronic airway inflammation and structural change with associated airway dysfunction [1] . It is defined by a history of respiratory symptoms (such as wheeze, shortness of breath, chest tightness and cough), which vary over time and in intensity, together with variable expiratory airflow limitation [1] . Asthma affects approximately 300 million individuals worldwide, with prevalence rates ranging from 1% to 16% in different countries [2] . In the UK, 5.4 million people currently receive treatment for asthma (1.1 million children [1 in 11] and 4.3 million adults [1 in 12] ) and, on average, three people per day die from asthma [3] .
It is now clear that asthma comprises various disease subtypes with similar clinical manifestations, but with differing underlying pathophysiological mechanisms [1] . The classification of asthma has consequently evolved as understanding regarding its pathophysiology has increased. Having initially been categorized in terms of 'allergic' or 'non-allergic' asthma, a distinction was then made between 'eosinophilic' ('type 2 high') and 'non-eosinophilic' ('type 2 low') asthma. Advances in disease understanding subsequently indicated that there may be subgroups of type 2 high asthma that differ in terms of both the presence of underlying allergy and the potential source of type 2 cytokines. This led to the current concept of 'type 2 (T2) asthma', which is characterized by high levels of type 2 interleukins (ILs), such as IL-4, IL-5 and IL-13, and involves type 2 helper T cells (Th2 cells), mast cells, basophils, B cells and type 2 innate lymphoid cells (ILC2s) [4] [5] [6] . It is currently believed that Th2 cells and ILC2s are primarily responsible for the production of the majority of type 2 cytokines in the airway, including IL-4, IL-5, IL-9 and IL-13 [5, 7] . The prolonged presence of activated inflammatory cells leads to chronic inflammation and airway remodelling [8] .
Since the 1990s, efforts to characterize asthma in terms of clinical, physiological and pathological parameters have led to the concept of asthma 'phenotypes' and 'endotypes' [9] [10] [11] [12] [13] . The term 'phenotype' is used to denote a recognizable cluster of similar clinically observable characteristics, which can be identified using statistical methods (e.g. cluster analysis) without establishing an underlying aetiology or pathophysiology [12, 14, 15] . By contrast, the term 'endotype' is used to describe a disease subtype with a clearly elucidated pathophysiology [15] . Current approaches to asthma stratification primarily rely on identifying phenotypes, as the level of understanding required to establish endotypes has, in general, not yet been achieved [15] .
Asthma can be stratified in many ways: in terms of clinical history, physiology, inflammatory phenotype profile or biomarkers, and also in terms of therapeutic response to individual treatments. Stratification is central to the effective management of asthma, as it facilitates the personalization of treatment tailored to the individual's specific needs. This is particularly important with the emergence of targeted forms of asthma therapy, such as those targeting specific pro-inflammatory cytokines [16] .
Asthma management in the UK is currently based on empirical stepwise treatment, with inhaled corticosteroids being standard of care for mild asthma, and combinations of inhaled corticosteroids and long-acting beta agonist therapy plus further add-on therapies, as required, for more severe asthma [17] . International guidelines define severe asthma as 'asthma that requires treatment with high-dose inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming "uncontrolled," or that remains 'uncontrolled' despite this therapy' [18] . Approximately 3-5% of asthma sufferers are unresponsive to available treatments and severe, therapy-resistant asthma has become increasingly recognized as a major unmet need [18, 19] . Moreover, severe refractory asthma is associated with a substantial burden in terms of healthcare costs. In the UK, the direct treatment costs from a National Health Service perspective, based on data from the British Thoracic Difficult Asthma Registry, were estimated to be £2912-4217 per patient per year [20] . Identification of therapy resistance in difficult-to-treat asthma is hampered by poor adherence to treatment, which is known to be a problem in many asthma patients [21, 22] . However, there is also a subset of patients who have poorly controlled asthma with persistent type 2 inflammation, despite adherence with high-dose inhaled steroids. These patients often progress to systemic steroid treatment, which is associated with significant morbidity [23] , and some of the new therapies targeting type 2 inflammation are likely to be of value for treating such patients in the future. It is therefore important to identify patient subgroups likely to benefit from targeted forms of treatment [19, 24] . As the diagnosis of asthma is usually based on reported symptomatology and lung function tests [25] , which are unable to assess airway inflammation and stratify the disease into discriminated phenotypes, there is a need for biomarkers to help with the accurate identification of clinically relevant phenotypes, not only to potentially aid diagnosis and inform prognosis, but also to guide treatment decisions, and predict and monitor treatment response.
A biomarker is defined as 'a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention' [26] . The ideal characteristics of a biomarker are outlined in Table 1 [15, [27] [28] [29] . Essentially, the ideal biomarker should be easily measurable, have the ability to identify a mechanism known to be important in the pathogenesis of the disease, be reliable and reproducible in the clinical setting and be cost-effective. It should ideally be mechanistically linked to the therapeutic target and responsive to intervention [15, [27] [28] [29] . Biomarkers for asthma have been identified from a variety of sources, including the airway, exhaled breath and blood. The primary focus of this article is the role of T2 biomarkers in asthma management.
Airway biomarkers
Bronchial biopsy has been considered the 'gold standard' for investigating airway inflammation and tissue remodelling, but it is invasive, costly, complex to perform and not readily accessible in clinics or research centres [28] . Bronchoalveolar lavage also involves bronchoscopy, is often poorly tolerated by patients with asthma and also has to be conducted in a specialized hospital, preventing its widespread use in routine clinical practice [15] . Sputum induction is less invasive and more cost-effective than bronchoalveolar lavage, but it is still invasive and too technically complex and difficult to standardize for routine practice, and therefore generally only used in specialized centres and usually in a research setting [15, 25] . Induced sputum and bronchoalveolar lavage contain cells (such as eosinophils and neutrophils) and supernatant containing cytokines, which can be used to predict asthma severity and exacerbations [25, 28] . Indeed, the discernment of distinct inflammatory phenotypes through analysis of the cellular component of induced sputum is an early example of how biomarkers can be used to achieve asthma stratification [30] , although the utility of these particular biomarkers in the personalization of treatment is unclear [15] .
Biomarkers in exhaled breath
Fractional exhaled nitric oxide (FeNO)
The measurement of FeNO is a relatively simple, fast, non-invasive and reproducible technique that has been used as a surrogate measure of airway inflammation in asthma [15, 29] . The American Thoracic Society and European Respiratory Society have standardized a method to measure FeNO [31] , providing a simple, fast, non-invasive and reproducible technique in asthma management [15] . Findings from the Isle of Wight birth cohort study indicated that FeNO may be a useful biomarker for atopic asthma (where atopy was defined as having ≥ 1 positive skin prick test to either a food or aeroallergen) [32] . High FeNO levels (> 47 ppb) have been shown to be associated with airway eosinophilia and corticosteroid responsiveness [33] and also to be prognostic for asthma exacerbations [34] . Similarly, high (≥ 19.5 ppb) vs. low (< 19.5 ppb) FeNO levels have been associated with greater treatment effects with omalizumab, a targeted anti-immunoglobulin E (IgE) therapy [35] . Indeed, of the three potential biomarkers investigated in this study (FeNO, blood eosinophil count, serum periostin level), a high level of FeNO was the strongest predictor of response to omalizumab therapy [35] . The degree of suppression of FeNO resulting from inhaled corticosteroid therapy has been used to identify non-adherence to this treatment in a difficultto-treat asthma population [36] , and it has been suggested that this test could be used to help identify patients who are truly refractory to corticosteroid treatment, before considering dose escalation or the introduction of more costly targeted forms of therapy [22] . In addition, a treatment algorithm in which FeNO concentrations were used to adjust patients' inhaled corticosteroid dose during pregnancy was shown to significantly reduce the frequency of asthma exacerbations [37] . However, the clinical utility of FeNO measurement in asthma is not clear-cut, as studies investigating the association between asthma control and FeNO have yielded inconsistent results [25] , perhaps partly because FeNO levels can be influenced by factors other than asthma, including age, medication use, smoking status and dietary factors [38] . Controversy over the clinical utility of FeNO as biomarker for asthma is reflected in current treatment guidelines. In the UK, the National Institute of Health and Care Excellence Diagnostics Draft Guidance 12 (due for formal publication in 2017) advocates the use of FeNO testing to help diagnose asthma in adults and children [39] ; however, the Global Initiative for Asthma has concluded that FeNO cannot be recommended for asthma diagnosis and therapy monitoring [1] .
Volatile organic compounds (VOCs)
VOCs can be measured in exhaled breath and their profile patterns might potentially be used to diagnose and distinguish between asthma and other conditions (e.g. chronic obstructive pulmonary disease), and discriminate between different asthma phenotypes [15, 40] . 'Electronic nose' technology provides a means of studying VOCs in individual patients, by utilizing an array of sensors that react with different VOCs to generate a specific 'breath print' [41] . This approach has demonstrated high sensitivity and specificity for discriminating between asthma, chronic obstructive pulmonary disease and healthy patients [42] , and has been used in [40] . It has also shown greater accuracy than measurement of FeNO or eosinophils for predicting responsiveness to corticosteroids [43] . However, it does not appear to be able to distinguish mild asthma from severe asthma [44] . The clinical utility of VOC measurement needs to be validated in a large asthma cohort; longitudinal data and guidelines for VOC measurement are also lacking [25] .
Exhaled breath condensate
Exhaled breath condensate collection is an easy, noninvasive, reproducible technique that can be used to measure several asthma biomarkers, including pH, markers of oxidative stress (including hydrogen peroxide), microRNA profiles, lipoxins, cytokines and leukotrienes [25, 28, 45] . However, the technique is still in the research phase; a standardized methodology for exhaled breath condensate collection is required and reference values need to be established.
Exhaled breath temperature
Exhaled breath temperature is another potential biomarker for asthma, as blood flow in asthmatic airways is increased, resulting in a measurable increase in exhaled breath temperature [46, 47] . Exhaled breath temperature is unlikely to be able to distinguish between asthma phenotypes, but it could potentially be used to monitor efficacy of asthma treatment, although this requires further research [15] .
Biomarkers in blood
Biomarkers measured in blood are relatively non-invasive, and less technically demanding than the assessment of biomarkers from exhaled breath. Several blood biomarkers are clinically well established and already used to help characterize asthma subtypes and monitor response to treatment. Certain novel blood biomarkers have also been identified, which may impact asthma management in the future.
Eosinophil counts
Peripheral blood eosinophil counts have been extensively studied as a potential biomarker for asthma. Eosinophils are important drivers of severe exacerbations in asthma [13] , and blood eosinophil counts reflect inflammation in the asthmatic airway, being useful in the early detection of exacerbations and the regulation of steroid dosage [48] .
Mepolizumab, a humanized monoclonal antibody against IL-5, is a selective and effective inhibitor of eosinophilic inflammation [49] . Mepolizumab treatment has been shown to significantly decrease the frequency of exacerbations in patients with refractory asthma and evidence of eosinophilic airway inflammation, despite treatment with high doses of corticosteroids [13] . These findings have been further supported by more recent trials of mepolizumab treatment in patients with eosinophilic asthma [50, 51] . The benefits of treatment are closely associated with the blood eosinophil count, and the clinical response is marked in patients with pre-treatment eosinophilia and absent in patients with a count < 150/lL [50] . Similarly, Phase II trials of the anti-IL-5 agent, benralizumab, have demonstrated its effectiveness in reducing asthma exacerbation and improving lung function and asthma control in patients with uncontrolled eosinophilic asthma and acute asthma [52] [53] [54] , and Phase III trials of the anti-IL-5 agent, reslizumab, have demonstrated its effectiveness in improving asthma control and symptoms, lung function and quality of life in patients with inadequately controlled asthma and elevated blood eosinophil counts [55] [56] [57] .
Blood eosinophil levels have also been shown to predict treatment benefit from biological therapies targeting IgE, IL-4 and IL-13 in patients with asthma [35, 58, 59] . For example, in the EXTRA study, in which patients with uncontrolled severe persistent allergic asthma received 48 weeks of omalizumab treatment, patients with pre-defined high baseline levels of peripheral blood eosinophil counts (≥ 260/lL) experienced a significant reduction in protocol-defined exacerbations (-32%; P = 0.005), whereas those with pre-defined low baseline levels (< 260/lL) did not (-9%; P = 0.54) [35] . In a randomized, double-blind, placebo-controlled study of lebrikizumab (a monoclonal antibody to IL-13), conducted in adults with asthma who were inadequately controlled despite inhaled glucocorticoid therapy, there was a trend towards a lower rate of protocol-defined exacerbations in patients treated with lebrikizumab, compared with those treated with placebo, after 24 weeks (P = 0.16) [58] . However, in the pre-specified 'Th2 high' subgroup, defined on the basis of baseline peripheral blood eosinophil count and serum IgE level, the rate of exacerbations was 60% lower in the lebrikizumab group than in the placebo group (P = 0.03) [58] .
Although peripheral blood eosinophil data are readily available from a standard complete blood count, the clinical utility of the blood eosinophil count as a biomarker for asthma may be limited in some situations by its low specificity for eosinophilic airway inflammation, as a raised count can also be caused by other allergies, autoimmune disease and parasitic infections [25] . In addition, the sensitivity of blood eosinophil levels as a biomarker for asthma is likely to decrease with the use of anti-IL-5 treatment, due to the differential effect of such treatment on eosinophilic inflammation in different tissue compartments. Consequently, a suppressed peripheral blood eosinophil count in patients receiving anti-IL-5 therapy does not reliably inform the level of underlying eosinophilic airway inflammation required to determine therapy response when symptoms and/or exacerbations remain persistent.
Activation profile of eosinophils
Changes in the activation profile of eosinophils in peripheral blood reflect their response to pro-and antiinflammatory signals; for example, membrane-bound integrins become activated when eosinophils are primed to leave the circulation and enter tissue [60] . Such changes have been used to diagnose the type and severity of allergic asthma [25] . In a double-blind, placebocontrolled study of inhaled corticosteroid withdrawal in patients with mild asthma, activation of b1 integrins (identified using a monoclonal antibody) predicted decreased forced expiratory volume in 1 s more effectively than either FeNO or the percentage of eosinophils in sputum, and correlated with FeNO following inhaled corticosteroid withdrawal [61, 62] . However, such differences in the activation profile of eosinophils are likely to be too subtle for routine application [25] .
Periostin
Genomewide gene expression studies in bronchial epithelial cells identified two subsets of patients, 'Th2 high' and 'Th2 low' patients [63] . This terminology was based on the observation that the highest expressed genes in the 'Th2 high' population were all inducible by IL-13. Moreover, an analysis of gene expression in bronchial biopsies from the same patients demonstrated differences in IL-13 gene expression levels between patients with 'Th2-high' and 'Th2-low' asthma or healthy controls [63] . However, even with highly sensitive assays, differences in serum IL-13 levels cannot reliably be detected [64] . There is therefore a need for a surrogate systemic biomarker of Th2-driven asthma (recently recognized as T2 asthma) that is mechanistically linked to IL-13. Periostin, the gene for which was one of those most highly expressed in the Th2 high population in the study by Woodruff et al. [63] , is induced by IL-4 and IL-13 in airway epithelial cells and lung fibroblasts [65] . Periostin is a matricellular protein that has been identified as a component of subepithelial fibrosis in bronchial asthma [65, 66] and which has a potential role in eosinophilic airway inflammation [67] and regulation of mucus production [68] . These mechanisms suggest that periostin is a potential mediator of asthma [69] . Importantly, periostin has been shown to be a systemic biomarker of T2, IL-13-driven, corticosteroid-responsive asthma [63, 66] . In the BOBCAT study, conducted in patients with asthma who remained symptomatic despite maximal inhaled corticosteroid treatment, serum periostin was found to predict eosinophilic airway inflammation (defined as ≥ 22 tissue eosinophils/mm 2 on bronchial biopsy or sputum eosinophilia ≥ 3%) better than FeNO levels, blood eosinophil counts or serum IgE levels ( Fig. 1) [70] . However, in another study, serum periostin was unable to distinguish eosinophilic asthma (defined as sputum eosinophils ≥ 3%) from noneosinophilic airway inflammation, whereas blood eosinophil count and FeNO level were able to do so [71] .
Serum periostin levels in patients with asthma have been shown to be significantly higher than those in healthy subjects, and to correlate positively with blood eosinophil counts, serum IgE and eosinophil cationic protein levels (P < 0.05) [72] . High serum periostin levels have also been shown to predict asthmatic activity after reduction in inhaled corticosteroids in patients with apparently stable, well-controlled asthma [73] . Similarly, serum periostin appears to be a useful biomarker for the development of airflow limitation in patients with asthma on prolonged treatment with inhaled corticosteroids [74] . These findings indicate that serum periostin may be a biomarker for responsiveness to inhaled corticosteroid therapy, which may therefore be useful in helping to identify patients as suitable candidates for alternative targeted forms of therapy [75] .
Serum periostin has also been investigated as a biomarker for predicting treatment response to targeted Fig. 1 . Receiver operating characteristic curve analysis of the sensitivity and specificity of serum periostin, FeNO, serum IgE levels and blood eosinophil numbers as biomarkers for eosinophilic airway inflammation. Adapted from Jia et al., 2012 with permission from Elsevier [70] . AUC, area under the curve; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E. asthma therapies. For example, patients with asthma with high baseline levels of serum periostin reportedly benefit most from anti-IL-13 therapy with lebrikizumab and tralokinumab [58, 76, 77] . Recently, topline results from 2 Phase III, randomized, double-blind, placebocontrolled studies evaluating the efficacy and safety of lebrikizumab in patients with severe asthma were released (LAVOLTA I and II) [78] . LAVOLTA I met its primary endpoint by demonstrating a significant reduction in the rate of asthma exacerbations in patients with high levels of serum periostin or blood eosinophils. However, the exacerbation reduction results observed in LAVOLTA II did not attain statistical significance [78] . The potential prognostic role of periostin as a biomarker to predict exacerbations and to help guide asthma therapy is being further investigated in ongoing clinical trials, such as the UK Refractory Asthma Stratification Programme (RASP-UK; see 'Implications of biomarkers of type 2 inflammation for current clinical practice' section) [24] .
Current evidence suggests that periostin can help identify patients with T2 asthma, but additional biomarkers are likely to be required in order to further subdifferentiate this phenotype [15] . The use of periostin as a biomarker in asthma management is currently limited by the need for well-established and validated cut-off values for high and low serum periostin levels, and thus the need for standardized measurement techniques. In addition, the specificity of periostin for asthma may be confounded by the presence of several factors, including comorbidities in which it is also known to be involved, such as metastatic cancer, renal injury, bone fracture and osteoporosis [79] [80] [81] .
Chitinase-like protein YKL-40
Serum levels of the chitinase-like protein, YKL-40, have been shown to be significantly elevated in patients with asthma vs. controls [82] [83] [84] . However, reports regarding correlations between serum YKL-40 levels and asthma severity or other asthma biomarker levels (eosinophils, total serum IgE, FeNO) have been inconsistent [70, [82] [83] [84] [85] . YKL-40 polymorphisms have been shown to be associated with asthma, bronchial hyperresponsiveness and reduced lung function [86] . It remains to be determined whether YKL-40 is involved in the pathophysiology of asthma or is simply a marker of extracellular tissue remodelling [87] , and its clinical utility in asthma management remains to be established.
ILC2S
Emerging evidence has indicated that activated ILC2s are capable of producing large amounts of inflammatory cytokines and may play a crucial role in T2 asthma [88] . In a recent study conducted in 150 patients with mild-to-moderate asthma and 42 healthy controls, the percentage of ILC2s in peripheral blood was shown to correlate significantly with sputum eosinophil counts (P < 0.001), and to have a sensitivity of 67.7% and a specificity of 95.3% when used to distinguish eosinophilic from non-eosinophilic patients with asthma [89] . The percentage of ILC2s in peripheral blood therefore appears to be a surrogate marker of airway eosinophilic inflammation [89] , although the clinical utility of this as a potential biomarker in asthma management is likely to be limited by difficulties in measuring ILC2 counts.
IgE
Serum levels of total and allergen-specific IgE have been considered as potential biomarkers for study population characterization and for the assessment of effectiveness in intervention studies in asthma [90] . However, in clinical trials of the anti-IgE therapy, omalizumab, pre-treatment levels of total IgE or antigenspecific IgE were inconsistent in predicting response to treatment [91, 92] . The clinical utility of measuring IgE serum levels may be limited by low specificity [25] .
Other circulating biomarkers
Many other circulating molecules and proteins have been investigated as potential biomarkers for asthma (Table 2 ). Whilst some of these are related to clinically important features cross-sectionally, we do not currently have evidence that they are prognostic or capable of predicting treatment responses.
Implications of biomarkers of type 2 inflammation for current clinical practice
The management of severe asthma remains a daily challenge as we currently have no gold standard diagnostic test, easy measure of adherence to prescribed therapies or accurate predictor of future risk. Failure to respond to high-dose inhaled corticosteroids in difficult-to-control asthma may either be due to non-adherence to treatment (which occurs in 30-50% of patients) or may be due to persistent type 2 inflammation, which is relatively resistant to corticosteroid therapy. This latter group of patients requires additional treatment with agents that specifically target type 2 mechanisms (such as anti-IL-5 and anti-IL-13 treatments) [24] . Conversely, patients with severe asthma frequently suffer from multiple comorbidities and may continue to be symptomatic even when their underlying airway inflammation is well controlled. RASP-UK is currently conducting an objective assessment of corticosteroid Non-specific marker of systemic inflammation that can be routinely measured in clinical practice [111] CRP levels shown to be increased in patients with asthma vs. controls [112] (continued) adherence in patients with severe asthma and investigating the use of novel biomarker stratification strategies to improve clinical management [24] . Specifically, the study will identify patients with high levels of T2 asthma biomarkers (periostin, eosinophils, FeNO) when adherent to high-dose corticosteroid therapy as appropriate candidates for novel biological treatments that target the T2 cytokine axis [24] . It is hoped that such stratification will enable patients to receive the most appropriate treatment, thus optimizing the use of relatively expensive targeted therapies. RASP-UK will also compare the use of a composite biomarker score, comprising FeNO, serum periostin and blood eosinophils, to guide corticosteroid therapy vs. conventional symptombased guidelines, thereby potentially helping to avoid unnecessary morbidity due to excessive corticosteroid exposure [24] . U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) is a 5-year European-wide project that aims to identify biomarkers for severe asthma [116] . It will make use of multi-dimensional phenotyping using a series of 'omics platforms', in which a large number of parameters will be assessed at one time, allowing researchers to develop a 'handprint' of severe asthma subtypes [116] . It is hoped that the project will help refine diagnostic criteria for asthma phenotypes and establish whether these can predict responsiveness to new and existing treatments [116] , thereby providing a template for asthma stratification and personalization of treatment. Hopefully, these and other ongoing clinical studies will allow the use of blood biomarkers in asthma to move from the research setting to routine clinical practice.
The emergence of a multiplicity of novel biomarkers for asthma, including those developed as companion diagnostics for targeted therapies, could lead to confusion and over-complexity in clinical practice. It is hoped that studies such as RASP-UK and U-BIOPRED will provide the strength of data required to enable the development of evidence-based guidelines detailing how and when specific biomarkers should be used, in terms of guiding prognosis, informing treatment decisions and monitoring subsequent response to therapy. To date, research has predominantly focussed on the characterization of biomarkers for T2 asthma. However, T2 asthma represents only one of the currently recognized asthma phenotypes. Non-eosinophilic airway inflammation occurs in approximately 50% of patients with asthma, and non-eosinophilic asthma has been further subdivided into neutrophilic, mixed granulocytic and pauci-granulocytic (or pauci-immune) subtypes [30, 117, 118] . The proportions of these subtypes are currently unclear, due to variations in the cut-offs used to define them [117] . For example, non-eosinophilic asthma has been defined as asthma associated with a sputum eosinophil count of either ≤ 2% or ≤ 3%, whilst neutrophilic asthma has been defined using sputum neutrophil cut-offs ranging from ≥ 60% to > 76% [119] . Crucially, non-eosinophilic asthma is insensitive to corticosteroid therapy [9] . To date, biological agents developed to target mediators of non-eosinophilic inflammation (e.g. IL-17) and novel small molecules targeting neutrophilic inflammation (e.g. chemokine receptor 2 antagonists) have failed to show convincing beneficial effects in clinical trials [117, 120, 121] . There is therefore an ongoing need for research to further identify and characterize biomarkers of non-T2 asthma, to aid diagnosis, inform prognosis and help guide the development of effective targeted therapies. The characterization of non-T2 biomarkers is also important for the characterization and management of T2 asthma, as the absence of expression of a T2 biomarker does not necessarily imply a non-T2 status, and biomarkers for non-T2 asthma will therefore aid the differential diagnosis of both non-T2 and T2 phenotypes.
Conclusions
The clinical management of airway diseases is not straightforward and is confounded by the use of diagnostic labels implying a probable natural history, which can result in suboptimal management paradigms and unhelpfully influence expectations about treatment outcomes [122, 123] . Asthma is now known to be heterogeneous with a number of underlying pathophysiological mechanisms, which may require very different treatment approaches. Consequently, there has been an increasing focus on identifying specific, well-defined and treatable aspects of disease [123, 124] . The identification and evidence-based clinical application of reliable biomarkers that: (1) assist in the diagnosis of asthma, (2) provide prognostic information and (3) identify underlying pathophysiological disease mechanism(s) to target treatment will be major areas of advance in coming years. Several biomarkers are currently available that assist in these areas (Table 3) but ongoing research will help clarify further the potential use of these and other biomarkers in routine practice, and provide greater understanding and evidence for the clinical utility of a range of emerging novel potential biomarkers.
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